Main Article Content

Abstract

The hepatitis D virus causes liver disease. It affects all ages. Some call it "delta hepatitis" (HDV). Hepatitis D patients have previously had hepatitis B, which is why they have this illness. Hepatitis D is spread when contaminated blood or bodily fluids come into contact with an uninfected person's body. Hepatitis D can be an acute infection or a chronic illness, depending on the person. Hepatitis D can produce severe symptoms, liver damage that lasts a lifetime, and even death. Hepatitis B and D viruses can infect people at the same time (coinfection) or they might develop hepatitis D after getting hepatitis B (reverse coinfection) (a condition known as "superinfection"). Hepatitis D is not prevented by immunisation. Hepatitis B vaccination, on the other hand, protects against hepatitis D infection.

Keywords

HDV hepatitis D virus delta hepatitis coinfection

Article Details

How to Cite
Yasir , S. J. ., & Al- Makhzoomy, T. A. kareem. (2021). Hepatitis delta virus (HDV): Some Details and features. Medical Science Journal for Advance Research, 2(3), 107–134. https://doi.org/10.46966/msjar.v2i3.30

References

  1. "Hepatitis D". www. Who . int.2020.
  2. Fattovich G , Giustina G , Christensen E, Pantalena M , Zagni I , Realdi G, Schalm SW (2000). "Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis ". Gut. 46 (3): 420–6.
  3. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q (2020). "Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection". The Journal of Infectious Diseases. 221 (10): 1677–1687.
  4. "Hepatitis (Viral) NIDDK". The National Institute of Diabetes and Digestive and Kidney Diseases. 2020.
  5. Farci P (2003). "Delta hepatitis: an update". Journal of Hepatology. 39 (1): S212–9.
  6. Magnius L, Taylor J, Mason WS, Sureau C, Dény P, Norder H (2018). "ICTV Virus Taxonomy Profile: Deltavirus". The Journal of General Virology. 99 (12): 1565–1566. .
  7. Makino S , Chang MF , Shieh CK , Kamahora T , Vannier DM , Govindarajan S , Lai MM (1987). "Molecular cloning and sequencing of a human hepatitis delta (delta) virus RNA". Nature. 329 (6137): 343–6.
  8. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, Verme G (1977). "Immunofluorescence detection of new antigen-antibody system (delta / anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers". Gut. 18 (12): 997–1003
  9. Rizzetto M, Canese MG, Purcell RH, London WT, Sly LD, Gerin JL (1981). "Experimental HBV and delta infections of chimpanzees: occurrence and significance of intrahepatic immune complexes of HBcAg and delta antigen". Hepatology. 1 (6): 567–74.
  10. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, Mullenbach GT, Denniston KJ, Gerin JL, Houghton M (1986). "Structure, sequence and expression of the hepatitis delta (delta) viral genome". Nature. 323 (6088): 508–14.
  11. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (2005). "Deltavirus". Eight Report of the International Committee on Taxonomy of Viruses. London: 735–8.
  12. Lin JH, Chang MF, Baker SC, Govindarajan S, Lai MM. Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. J Virol. 1990; 64: 4051–4058.
  13. Wang CJ, Chen PJ, Wu JC, Patel D, Chen DS. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. J Virol. 1991; 65: 6630–6636.
  14. Lai MM. Molecular biologic and pathogenetic analysis of hepatitis delta virus. J Hepatol. 1995; 22: 127–131.
  15. Casaca A, Fardilha M, da Cruz e Silva E, Cunha C. The heterogeneous ribonuclear protein C interacts with the hepatitis delta virus small antigen. Virol J. 2011;8:358.
  16. Gudima S, Chang J, Moraleda G, Azvolinsky A, Taylor J. Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol. 2002; 76: 3709–3719.
  17. Flores R, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. Semin Liver Dis. 2012; 32: 201–210.
  18. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012; 1: 71–78.
  19. Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. Viruses. 2010; 2: 189–212.
  20. Flores R, Grubb D, Elleuch A, Nohales MÁ, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. RNA Biol. 2011; 8: 200–206.
  21. Huang CR , Lo SJ. Evolution and diversity of the human hepatitis d virus genome. AdvBioinformatics. 2010.Epub ahead of print.
  22. Sikora D, Greco-Stewart VS, Miron P, Pelchat M. The hepatitis delta virus RNA genome interacts with eEF1A1, p54 (nrb), hnRNP-L, GAPDH and ASF/SF2. Virology. 2009; 390 :71–g78.
  23. "Virus Taxonomy: 2020 Release". International Committee on Taxonomy of Viruses (ICTV). March 2021.
  24. Zuccola HJ, Rozzelle JE, Lemon SM, Erickson BW, Hogle JM (1998). "Structural basis of the oligomerization of hepatitis delta antigen". Structure. 6 (7): 821–30.
  25. This article incorporates text from the public domain Pfam and InterPro: IPR002506
  26. Elena SF, Dopazo J, Flores R, Diener TO, Moya A (1991). "Phylogeny of viroids, viroidlike satellite RNAs, and the viroidlike domain of hepatitis delta virus RNA". Proceedings of the National Academy of Sciences of the United States of America. 88 (13): 5631–4.
  27. Sureau C (2006). "The role of the HBV envelope proteins in the HDV replication cycle". Hepatitis Delta Virus. Current Topics in Microbiology and Immunology. 307. pp. 113–31.
  28. Saldanha JA, Thomas HC, Monjardino JP (July 1990). "Cloning and sequencing of RNA of hepatitis delta virus isolated from human serum". The Journal of General Virology. 71 (7): 1603–6.
  29. Miao Z, Zhang S, Ma Z, Hakim MS, Wang W, Peppelenbosch MP, Pan Q (2019). "Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus". Journal of Viral Hepatitis. 26 (1): 183–190.
  30. Wang K-S, Choo Q-L, Weiner AJ. et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature. 1986; 323: 508–513.
  31. Kuo MY-P, Goldberg J, Coates L. et al. Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: Sequence, structure, and applications. J Virol. 1988; 62: 1855–1861 15 Structure and Replication of Hepatitis Delta Virus RNA.
  32. Kos A, Dijkema R, Arnberg AC. et al. The hepatitis delta (ä) virus possesses a circular RNA. Nature. 1986; 323: 558–560.
  33. Lazinski DW, Taylor JM. Expression of hepatitis delta virus RNA deletions: cs and trans requirements for self-cleavage, ligation, and RNA packaging. J Virol. 1994; 68: 2879–2888.
  34. Loss P, Schmitz M, Steger G. et al. Formation of a thermodynamically metastable structure containing hairpin II is critical for infectivity of potato spindle tuber viroid RNA. EMBO J. 1991; 10: 719–727.
  35. Gudima S, Wu S-Y, Chiang C-M. et al. Origin of the hepatitis delta virus mRNA. J Virol. 2000; 74: 7204–7210.
  36. Hsieh S-Y, Chao M, Coates L. et al. Hepatitis delta virus genome replication: A polyadenylated mRNA for delta antigen. J Virol. 1990; 64: 3192–3198.
  37. Chen P-J, Kalpana G, Goldberg J. et al. Structure and replication of the genome of hepatitis ä Proc Natl Acad Sci USA. 1986; virus 83: 8774–8778.
  38. Gudima S, Dingle K, Wu T-T. et al. Characterization of the 5'-ends for polyadenylated RNAs synthesized during the replication of hepatitis delta virus. J Virol. 1999; 73: 6533–6539.
  39. Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr Top Microbiol Immunol. 2012; 353: –143.
  40. Tseng CH, Lai MM. Hepatitis delta virus RNA replication. Viruses. 2009; 1: 818–831.
  41. Wang YC, Huang CR, Chao M, Lo SJ. The C-terminal sequence of the large hepatitis delta antigen is variable but retains the ability to bind clathrin. Virol J. 2009; 6: 31.
  42. Wang T-C, Chao M. Molecular cloning and expression of the hepatitis delta virus genotype IIb genome. Biochem Biophys Res Commun. 2003; 303: 357–63.
  43. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature. 1986; 323: 508–14.
  44. Makino S, Chang MF, Shieh CK, Kamahora T, Vannier DM, Govindarajan S, et al. Molecular cloning and sequencing of a human hepatitis delta (delta) virus RNA. Nature1987; 329: 343–6.
  45. Glenn JS, White JM. Trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol. 1991; 65: 2357–61. Available from:
  46. Sheu SY, Chen KL, Lee YW, Lo SJ. No intermolecular interaction between the large hepatitis delta antigens is required for the secretion with hepatitis B surface antigen: a model of empty HDV particle. Virology. 1996; 218: 275–8.
  47. Sheu G-T. Initiation of hepatitis delta virus (HDV) replication: HDV RNA encoding the large delta antigen cannot replicate. J. Gen. Virol. 2002; 83: 2507–13. Available from:
  48. Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, Houghton M (1988). "A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope (s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta". Journal of Virology. 62 (2): 594–9.
  49. Jayan GC, Casey JL (2002). "Inhibition of hepatitis delta virus RNA editing by short inhibitory RNA-mediated knockdown of ADAR1 but not ADAR2 expression". Journal of Virology. 76 (23): 12399–404.
  50. Sato S , Cornillez-Ty C , Lazinski DW (2004). "By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression". Journal of Virology. 78 (15): 8120–34.
  51. Taylor JM (2006). "Structure and replication of hepatitis delta virus RNA". Hepatitis Delta Virus. Current Topics in Microbiology and Immunology. 307. pp. 1–23.
  52. Chang MF, Chen CJ, Chang SC (1994). "Mutational analysis of delta antigen: effect on assembly and replication of hepatitis delta virus". Journal of Virology. 68 (2): 646–53.
  53. Jaoudé GA, Sureau C (2005). "Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus". Journal of Virology. 79 (16): 10460–6.
  54. Radjef N, Gordien E, Ivaniushina V, Gault E, Anaïs P, Drugan T, Trinchet JC, Roulot D, Tamby M, Milinkovitch MC, Dény P (2004). "Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades". Journal of Virology. 78 (5): 2537–44.
  55. Taylor JM (2006). "Hepatitis delta virus". Virology. 344 (1): 71–6.
  56. Makino S, Chang MF, Shieh CK, Kamahora T, Vannier DM, Govindarajan S, et al. Molecular cloning and sequencing of a human hepatitis delta virus RNA. Nature. 1986;329(6137):343–6.
  57. World Health Organization. Global hepatitis report. Geneva: World Health Organization; 2017.
  58. Farci P. Delta hepatitis: an update. J Hepatol. 2003; 39: S212–9.
  59. Rizzetto M, Hepatitis D. Virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015; 5:a021576.
  60. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization; 2016.
  61. Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018.
  62. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2019.
  63. Lamas Longarela O, Schmidt TT, Schöneweis K, Romeo R, Wedemeyer H, Urban S, Schulze A. Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One. 2013; 8: e58340.
  64. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 2006; 43: 750–760.
  65. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1: e00049.
  66. Huang WH, Chen YS, Chen PJ. Nucleolar targeting of hepatitis delta antigen abolishes its ability to initiate viral antigenomic RNA replication. J Virol. 2008;82:692–699.
  67. Elena SF, Dopazo J, Florest R, Diener TO, Moya A. Phylogeny of viroids, viroidlike satellite RNAs, and the viroidlike domain of hepatitis 6 virus RNA. Evolution (N Y). 1991;88:5631–4.
  68. Tseng C-H, Lai MMC. Hepatitis delta virus RNA replication. Viruses. 2009; 1: 818–31.
  69. Taylor JM, Hepatitis D. Virus replication. Cold spring Harb. Perspect Med. 2015; 5: a021568.
  70. Chao M, Wang T-C, Lin C-C, Wang RY-L, Lin W-B, Lee S-E, et al. Analyses of a whole-genome inter-clade recombination map of hepatitis delta virus suggest a host polymerase-driven and viral RNA structure-promoted template-switching mechanism for viral RNA recombination. Oncotarget. 2017;
  71. Flores R, Grubb D, Elleuch A, Nohales M-Á, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. RNA Biol. 2011;8:200–6.
  72. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013; 10: 239.
  73. Watashi K, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014; 15: 2892–905.
  74. Li J, Tong S. From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor. Clin Mol Hepatol. 2015; 21: 193–9.
  75. Li W. The hepatitis B virus receptor. Annu Rev Cell Dev Biol. 2015; 31: annurev-cellbio-100814-125241.
  76. Xia YP, Yeh CT, Ou JH, Lai MM. Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol. 1992; 66: 914–21.
  77. Tavanez JP, Cunha C, Silva MCA, David E, Monjardino J, Carmo-Fonseca M. Hepatitis delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm. RNA. 2002; 8: 637–46.
  78. Alves C, Freitas N, Cunha C. Characterization of the nuclear localization signal of the hepatitis delta virus antigen. Virology. 2008;370:12–21.
  79. Yan H, Li W. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Dig Dis. 2015; 33: 388–96.
  80. Modahl LE, Macnaughton TB, Zhu N, Johnson DL, Lai MM. RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol. 2000; 20: 6030–9.
  81. Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the Hepatitis Delta virus. Viruses. 2010; 2: 189–212.
  82. Wu JC, Chiang TY, Shiue WK, Wang SY, Sheen IJ, Huang YH, et al. Recombination of hepatitis D virus RNA sequences and its implications. Mol Biol Evol.. 1999; 16: 1622–32.
  83. Wang T-C, Chao M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J Virol. 2005;79:2221–9..
  84. Lin C-C, Lee C-C, Lin S-H, Huang P-J, Li H-P, Chang Y-S, et al. RNA recombination in hepatitis delta virus: identification of a novel naturally occurring recombinant. J Microbiol Immunol Infect. 2015;
  85. Sy BT, Nguyen HM, Toan NL, Song LH, Tong HV, Wolboldt C, et al. Identification of a natural intergenotypic recombinant hepatitis delta virus genotype 1 and 2 in Vietnamese HBsAg-positive patients. J Viral Hepat. 2015; 22: 55–63.
  86. Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. . 2016; 64: S102–16.
  87. Hwang SB, Lai MM. Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J Virol. 1993; 67: 7659–62.
  88. Fu TB, Taylor J. The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J Virol. 1993; 67: 6965–72.
  89. Chang J, Nie X, Chang HE, Han Z, Taylor J. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol. 2008; 82: 1118–27.
  90. Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr Top Microbiol Immunol. 2012; 353: 123–43.
  91. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012). "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus". eLife. 1: e00049.
  92. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S (2006). "Characterization of a hepatitis B and hepatitis delta virus receptor binding site". Hepatology. 43 (4): 750–60.
  93. Schulze A, Schieck A, Ni Y, Mier W, Urban S (2010). "Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction". Journal of Virology. 84 (4): 1989–2000.
  94. Xia YP, Yeh CT, Ou JH, Lai MM (1992). "Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex". Journal of Virology. 66 (2): 914–21.
  95. Lehmann E, Brueckner F, Cramer P (2007). "Molecular basis of RNA-dependent RNA polymerase II activity". Nature. 450 (7168): 445–9.
  96. Filipovska J, Konarska MM (2000). "Specific HDV RNA - templated transcription by pol II in vitro". RNA. 6 (1): 41–54.
  97. Greco-Stewart VS, Schissel E, Pelchat M (March 2009). "The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III". Virology. 386 (1): 12–5.
  98. Li YJ, Macnaughton T, Gao L, Lai MM (2006). "RNA-templated replication of hepatitis delta virus: genomic and antigenomic RNAs associate with different nuclear bodies". Journal of Virology. 80 (13): 6478–86.
  99. Branch AD, Benenfeld BJ, Baroudy BM, Wells FV, Gerin JL, Robertson HD (1989). "An ultraviolet-sensitive RNA structural element in a viroid-like domain of the hepatitis delta virus". Science. 243 (4891): 649–52.
  100. Wu HN, Lin YJ, Lin FP, Makino S, Chang MF, Lai MM (1989). "Human hepatitis delta virus RNA subfragments contain an autocleavage activity". Proceedings of the National Academy of Sciences of the United States of America. 86 (6): 1831–5.
  101. J. M. Taylor, “Chapter 3 replication of the hepatitis delta virus RNA genome,” Advances in Virus Research, vol. 74, pp. 103–121, 2009.
  102. J. Chang, X. Nie, E. C. Ho, Z. Han, and J. Taylor, “Transcription of hepatitis delta virus RNA by RNA polymerase II,” Journal of Virology, vol. 82, no. 3, pp. 1118–1127, 2008.
  103. V. S. Greco-Stewart, P. Miron, A. Abrahem, and M. Pelchat, “The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome,” Virology, vol. 357, no. 1, pp. 68–78, 2007.
  104. J. Filipovska and M. M. Konarska, “Specific HDV RNA-templated transcription by pol II in vitro,” RNA, vol. 6, no. 1, pp. 41–54, 2000.
  105. T. B. Macnaughton, S. T. Shi, L. E. Modahl, and M. M. C. Lai, “Rolling circle replication of hepatitis delta virus RNA is carried out by two different cellular RNA polymerases,” Journal of Virology, vol. 76, no. 8, pp. 3920–3927, 2002.
  106. L. E. Modahl, T. B. Macnaughton, N. Zhu, D. L. Johnson, and M. M. C. Lai, “RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases,” Molecular and Cellular Biology, vol. 20, no. 16, pp. 6030–6039, 2000.
  107. J. P. Tavanez, C. Cunha, M. C. A. Silva, E. David, J. Monjardino, and M. Carmo-Fonseca, “Hepatitis delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm,” RNA, 8, 5: 637–646, 2002.
  108. V. S. Greco-Stewart, E. Schissel, and M. Pelchat, “The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III,” Virology, vol. 386, no. 1, pp. 12–15, 2009.
  109. J. Chang and J. Taylor, “In vivo RNA-directed transcription, with template switching, by a mammalian RNA polymerase,” EMBO Journal, vol. 21, no. 1-2, pp. 157–164, 2002.
  110. Poisson F, Roingeard P, Baillou A, Dubois F, Bonelli F, Calogero RA, Goudeau A (1993). "Characterization of RNA-binding domains of hepatitis delta antigen". The Journal of General Virology. 74 (Pt 11): 2473–8. T.-B. Fu and J. Taylor, “The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates,” Journal of Virology, vol. 67, no. 12, pp. 6965–6972, 1993.
  111. J. Taylor, “Virology of hepatitis D virus,” Seminars in Liver Disease, vol. 32, pp. 195–200, 2012.
  112. M. M. C. Lai, “RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus,” Journal of Virology, vol. 79, no. 13, pp. 7951–7958, 2005.
  113. AG. Polson, B. L. Bass, and J. L. Casey, “Erratum: RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase,” Nature, vol. 381, no. 6580, p. 346, 1996.
  114. J. L. Casey, “Hepatitis delta virus RNA editing,” in Hepatitis Delta Virus, H. Handa and Y. Yamaguchi, Eds., pp. 52–65, Georgetown Landes Bioscience, Austin, Tex, USA, 2006.
  115. S. Gudima, J. Chang, G. Moraleda, A. Azvolinsky, and J. Taylor, “Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA,” Journal of Virology, vol. 76, no. 8, pp. 3709–3719, 2002.
  116. M. Engelke, K. Mills, S. Seitz et al., “Characterization of a hepatitis B and hepatitis delta virus receptor binding site,” Hepatology, vol. 43, no. 4, pp. 750–760, 2006.
  117. D. Glebe and S. Urban, “Viral and cellular determinants involved in hepadnaviral entry,” World Journal of Gastroenterology, vol. 13, no. 1, pp. 22–38, 2007.
  118. J. M. Taylor and Z. Han, “Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis b virus,” PLoS ONE, vol. 5, no. 12, Article ID e15784, 2010.
  119. O. L. Longarela, T. T. Schmidt, K. Schöneweis, R. Romeo, H. Wedemeyer et al., “Proteoglycans act as cellular hepatitis delta virus attachment receptors,” PLoS ONE, vol. 8, Article ID e58340, 2013.
  120. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing et al., “Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus,” ELife, vol. 1, Article ID e00049, 2012.
  121. Niro GA, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep. 2012;14:9–14.
  122. Govindarajan S, Fields HA, Humphrey CD, Margolis HS. Pathologic and ultrastructural changes of acute and chronic delta hepatitis in an experimentally infected chimpanzee. Am J. Pathol. 1986; 122: 315–322.
  123. Kamimura T, Ponzetto A, Bonino F, Feinstone SM, Gerin JL, Purcell RH. Cytoplasmic tubular structures in liver of HBsAg carrier chimpanzees infected with delta agent and comparison with cytoplasmic structures in non-A, non-B hepatitis. Hepatology. 1983; 3: 631–637.
  124. Canese MG, Rizzetto M, Novara R, London WT, Purcell RH. Experimental infection of chimpanzees with the HBsAg-associated delta (delta) agent: an ultrastructural study. J. Med Virol. 1984; 13: 63–72.
  125. Ponzetto A, Hoyer BH, Popper H, Engle R, Purcell RH, Gerin JL. Titration of the infectivity of hepatitis D virus in chimpanzees. J Infect Dis. 1987; 155: 72–78.
  126. Cole SM, Gowans EJ, Macnaughton TB, Hall PD, Burrell CJ. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology. 1991; 13: 845–851.
  127. Lefkowitch J H , Goldstein H , Yatto R , Gerber MA. Cytopathic liver injury in acute delta virus hepatitis. Gastroenterology. 1987; 92: 1262–1266.
  128. Popper H, Thung SN, Gerber MA, Hadler SC, de Monzon M, Ponzetto A, Anzola E, Rivera D, Mondolfi A, Bracho A. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology. 1983; 3: 906–912.
  129. Casey JL, Gerin JL. The woodchuck model of HDV infection. Curr Top Microbiol Immunol. 2006; 307: 211–225.
  130. Casey JL, Tennant BC, Gerin JL. Genetic changes in hepatitis delta virus from acutely and chronically infected woodchucks. J Virol. 2006; 80: 6469–6477.
  131. Fiedler M, Lu M, Siegel F, Whipple J, Roggendorf M. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine. 2001; 19: 4618–4626.
  132. Fiedler M, Roggendorf M. Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax)model. Intervirology. 2001;44:154–161.
  133. Fiedler M , Roggendorf M. Immunology of HDV infection . Curr Top Microbiol Immunol. 2006;307:187–209.
  134. D’Ugo E, Canitano A, Catone S, Argentini C, Giuseppetti R, Orobello S, Palmieri G, Rapicetta M. Kinetics of WHV-HDV replication in acute fatal course of woodchuck hepatitis. Arch Virol. 2008; 153: 2069–2076.
  135. Hansson BG, Riesbeck K, Nordenfelt E, Weiland O. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response? Prog Clin Biol Res. 1991; 364: 421–427.
  136. Hourioux C, Sureau C, Poisson F, Brand D, Goudeau A, Roingeard P. Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains. J Gen Virol. 1998;79 (5):1115–1119.
  137. de Sousa BC, Cunha C. Development of mathematical models for the analysis of hepatitis delta virus viral dynamics. PLoS One. 2010;5 .
  138. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, Fagard R, Kremsdorf D, Dény P, Gordien E. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 2009; 90: 2759–2767.
  139. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellularcarcinoma. Gastroenterology. 2009; 136: 1629–1638.
  140. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.
  141. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, Quer J, Esteban R, Buti M. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010 ; 52: 658–664.
  142. Hadziyannis SJ. Hepatitis delta: an overview. In : Rizzetto M, Purcell RH, Gerin J L, and Verme G, editors. Viral Hepatitis and Liver Disease. Turin: Edizioni Minerva Medica; 1997. pp. 283–289.
  143. Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal AA, Zaid MA, et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol. 2003; 70 (4):529–36.
  144. Takahashi M, Nishizawa T, Gotanda Y, Tsuda F, Komatsu F, Kawabata T, et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol. 2004; 11: 392–8.
  145. Tsatsralt-Od B, Takahashi M, Endo K, Buyankhuu O, Baatarkhuu O, Nishizawa T, et al. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol. 2006;78(5):542–50.
  146. Khan A, Kurbanov F, Tanaka Y, Elkady A, Sugiyama M, Dustov A, et al. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. J Med Virol. 2008; 80 (2):268–76.
  147. Mohebbi SR, Zali N, Derakhshan F, Tahami A, Mashayekhi R, Amini-Bavil-Olyaee S, et al. Molecular epidemiology of hepatitis delta virus (HDV) in Iran: a preliminary report. J Med Virol. 2008; 80(12): 2092–9.
  148. Celik I, Karatayli E, Cevik E, Kabakçi SG, Karatayli SC, Dinç B, et al. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Arch Virol. 2011; 156: 2215–20.
  149. Perveen S, Nasir MI, Shahid SM, Azhar A, Khan OY. Phylogenetic analysis of HDV isolates from HBsAg positive patients in Karachi, Pakistan. Virol J. 2012; 9: 162.
  150. Bulut Y, Bahcecioglu IH, Aygun C, Oner PD, Ozercan I, Demirdag K. High genetic diversity of hepatitis delta virus in eastern Turkey. J Infect Dev Ctries. 2014; 8: 74–8.
  151. Attaran MS, Sharifi Z, Hosseini SM, Samei S, Ataee Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. APMIS. 2014; 122 (3):243–7.
  152. Shirvani-Dastgerdi E, Amini-Bavil-Olyaee S , Alavian SM , Trautwein C, Tacke F. Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression. Clin Microbiol Infect. 2015; 21: 510. e11–23.
  153. Yacoubi L, Brichler S, Mansour W, Le Gal F, Hammami W, Sadraoui A, et al. Molecular epidemiology of hepatitis B and Delta virus strains that spread in the Mediterranean North East Coast of Tunisia. J Clin Virol. 2015; 72: 126–32.
  154. Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol. 2001; 82: 2709–18.
  155. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006; 130 (6): 1625–35.
  156. Borzacov LM, de Figueiredo Nicolete LD, Souza LF, Dos Santos AO, Vieira DS, Salcedo JM. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. Int J Infect Dis. 2016; 46: 82–8.
  157. Watanabe H, Nagayama K, Enomoto N, Chinzei R, Yamashiro T, Izumi N, et al. Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J Gen Virol. 2003; 84: 3275–89.
  158. Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitisdelta virus. Emerg Infect Dis. 2006; 12: 1447–50.
  159. Radjef N, Gordien E, Ivaniushina V, Gault E, Anaïs P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004; 78 (5):2537–44.
  160. Gerber A, Gal FL, Dziri S, Alloui C, Roulot D, Abdesselam ZB, et al. Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years. J Hepatol. 2018; 68: S783.
  161. Spaan M, Carey I, Bruce M, Shang D, Dusheiko G, Agarwal K. Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses? J Viral Hepat. 2018; 25: S21.
  162. Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010; 202: 845–52.
  163. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015; 63(3): 586–92.
  164. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008; 80: 277–82.
  165. Rosenblum L, Darrow W, Witte J, Cohen J, French J, Gill PS, et al. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA. 1992; 267(18): 2477–81.
  166. Servant-Delmas A, Le Gal F, Gallian P, Gordien E, Laperche S. Increasing prevalence of HDV/HBV infection over 15 years in France. J Clin Virol. 2014; 59(2):126–8.
  167. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013; 59 (5): 949–56.
  168. Sagnelli E, Taliani G, Castelli F, Bartolozzi D, Cacopardo B, Armignacco O, et al. Chronic HBV infection in pregnant immigrants: a multicenter study of the Italian Society of Infectious and Tropical Diseases. New Microbiol. 2016;39:114–8.
  169. Rivas P, Herrero MD, Poveda E, Madejón A, Treviño A, Gutiérrez M, et al. Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain. Am J Trop Med Hyg. 2013; 88: 789–94.
  170. Wedemeyer H , Manns MP. Epidemiology , pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010; 7 (1): 31–40.
  171. Tang JR, Hantz O, Vitvitski L, Lamelin JP, Parana R, Cova L, Lesbordes JL, Trépo C. Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic. J Gen Virol. 1993; 74 (Pt 9):1827–1835.
  172. Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet. 1995;346:939–941.
  173. Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, Diaz RS. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis. 2009; 199: 1608–1611.
  174. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–947.
  175. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology. 2007; 132: 343–357.
  176. Shih HH, Sheen IJ, Su CW, Peng WL, Lin LH, Wu JC. Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. J Virol. 2012;86:9044–9054.
  177. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999; 18: 2449–2458.
  178. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001; 480-481: 243–268.
  179. Williams V, Brichler S, Khan E, Chami M, Dény P, Kremsdorf D, Gordien E. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. J Viral Hepat. 2012; 19: 744–753.
  180. Liao FT, Lee YJ, Ko JL, Tsai CC, Tseng CJ, Sheu GT. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. J Gen Virol. 2009; 90: 1124–1134.
  181. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? SaudiGastroenterol. 2012; 18: 18–22.
  182. World Health Organization. Hepatitis D: Fact Sheet. In: Media Centre. Geneva: World Health Organization; 2017.
  183. Perazzo H, Pacheco AG, Luz PM, Castro R, Hyde C, Fittipaldi J, et al. Age-standardized mortality rates related to viral hepatitis in Brazil. BMC Infect Dis. 2017;17:527.
  184. Crispim MA, Fraiji NA, Campello SC, Schriefer NA, Stefani MM, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC Infect Dis. 2014;14:94.
  185. di Filippo VD, Cortes-Mancera F, Payares E, Montes N, de la Hoz F, Arbelaez MP, et al. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia. Virol J. 2015;12:172
  186. Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics:utilization and testing in the united states. Virus Res. 2018.
  187. Braga WS, de Oliveira CM, de Araújo JR, Castilho Mda C, Rocha JM, Gimaque JB, et al. Chronic HDV/HBV co-infection: predictors of disease stage---a case series of HDV-3 patients. J Hepatol. 2014;61(6):1205–11.
  188. Khan AU, Waqar M, Akram M, Zaib M, Wasim M, Ahmad S, et al. True prevalence of twin HDV-HBV infection in Pakistan: a molecular approach. Virol J. 2011;8(1):420.
  189. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, et al. Hepatitis delta virus infection in Romania: prevalence and risk factors. J Gastrointestin Liver Dis. 2015; 24: 413–21.
  190. Dulger AC, Suvak B, Gonullu H, Gonullu E, Gultepe B, Aydın İ, et al. High prevalence of chronic hepatitis D virus infection in eastern Turkey: urbanization of the disease. Arch Med Sci. 2016; 12(2): 415–20.
  191. Uzun B, Şener AG, Güngör S, Afşar I, Demirci M. Evaluation of hepatitis delta virus (HDV) infection in blood donors in western Turkey. Transfus Apher Sci. 2014;50:388–91.
  192. Børresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, Panum I, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010; 17: 162–70.
  193. Langer BC, Frösner GG, von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat. 1997;4:339–49.
  194. Rex KF, Krarup HB, Laurberg P, Andersen S. Population-based comparative epidemiological survey of hepatitis B, D, and C among Inuit migrated to Denmark and in high endemic Greenland. Scand J Gastroenterol. 2012;47(6):692–701.
  195. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32(3):211–9.
  196. Zaki H, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr. 2003; 49: 371–4.
  197. Chakraborty P, Kailash U, Jain A, Goyal R, Gupta RK, Das BC, et al. Seroprevalence of hepatitis D virus in patients with hepatitis B virus-related liver diseases. Indian J Med Res. 2005; 122: 254–7.
  198. Mulyanto , Depamede SN , Surayah K , Tsuda F , Ichiyama K , Takahashi M , et al. A nationwide molecular epidemiological study on hepatitis B virus in Indonesia: identification of two novel subgenotypes, B8 and C7. Arch Virol. 2009; 154: 1047–59.
  199. Louisirirotchanakul S, Myint KS, Srimee B, Kanoksinsombat C, Khamboonruang C, Kunstadter P, et al. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health. 2002; 33: 837–44.
  200. Baatarkhuu O, Uugantsetseg G, Munkh-Orshikh D, Naranzul N, Badamjav S, Tserendagva D, et al. Viral hepatitis and liver diseases in Mongolia. Hepato-Gastroenterol. 2017; 7 (1): 68–72.
  201. Chen X, Oidovsambuu O, Liu P, Grosely R, Elazar M, Winn VD, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology. 2017; 66(6): 1739–49.
  202. Abbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol. 2010; 16: 554–62.
  203. Lin HH, Lee SS, Yu ML, Chang TT, Su CW, Hu BS, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015; 61: 1870–9.
  204. Sakugawa H, Nakasone H, Shokita H, Kawakami Y, Nakachi N, Adaniya H, et al. Seroepidemiological study on hepatitis delta virus infection in the Irabu Islands, Okinawa, Japan. J Gastroenterol Hepatol. 1997; 12 (4): 299–304.
  205. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Miyazato S, Kinjo F, et al. Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan. J Med Virol. 1999; 58: 366–72.
  206. Han M, Littlejohn M, Yuen L, Edwards R, Devi U, Bowden S, et al. Molecular epidemiology of hepatitis delta virus in the Western Pacific region. J Clin Virol. 2014; 61(1): 34–9.
  207. Dimitrakakis M, Gust I. HDV infection in the Western Pacific region. Prog Clin Biol Res. 1991; 364: 89–96.
  208. Tibbs CJ. Delta hepatitis in Kiribati: a pacific focus. J Med Virol. 1989; 29(2): 130–2.
  209. Sy BT, Ratsch BA, Toan NL, le Song H, Wollboldt C, Bryniok A, et al. High prevalence and significance of hepatitis D virus infection among treatment-naïve HBsAg-positive patients in Northern Vietnam. PLoS One. 2013; 8: e78094.
  210. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9): e609–16.
  211. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018; 142(12): 2471–7.
  212. World Health Organization. Summary tables of mortality estimates by cause, age and sex, globally and by region, 2000–2016. Geneva: World Health Organization; 2018.
  213. Casey JL. Hepatitis delta virus: Genetics and pathogenesis. Clin Lab Med. 1996; 16: 451–464.
  214. Modahl LE, Lai MM. Hepatitis delta virus: The molecular basis of laboratory diagnosis. Crit Rev Clin Lab Sci. 2000; 37: 45–92.
  215. Gudima S, Dingle K, Wu T-T. et al. Characterization of the 5'-ends for polyadenylated RNAs synthesized during the replication of hepatitis delta virus. J Virol. 1999; 73: 6533–6539.
  216. Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol. 2006; 307: 67–89.
  217. Casey JL, Bergmann KF, Brown TL, Gerin JL. Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci USA. 1992; 89: 7149-53.
  218. Casey J L, Gerin J L. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol. 1995; 69: 7593–600.
  219. Chao YC, Chang MF, Gust I, Lai MM. Sequence conservation and divergence of hepatitis delta virus RNA. Virology.1990; 178: 384–92.
  220. Lai MMC. RNA replication without RNA - dependent RNA polymerase: surprises from hepatitis delta virus. J Virol. 2005; 79 : 7951–8.
  221. Radjef N, Gordien E, Ivaniushina V, Gault E, Anaïs P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78:2537–44.
  222. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. 2006; 307: 151–71.
  223. Le Gal F, Gault E, Ripault M-P, Serpaggi J, Trinchet J-C, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis. 2006; 12: 1447–50.
  224. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.
  225. Farci P. Delta hepatitis: an update. J Hepatol. 2003; 39 (1):S212–9.
  226. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8:S10-4-3.
  227. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL. Geographic distribution and genetic variability of Hepatitis Delta virus genotype I. Virology. Academic Press. 1997; 234: 160–7.
  228. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA.. 1993; 90: 9016–20.
  229. Paraná R, Kay A, Molinet F, Viana S, Silva LK, Salcedo JM, et al. HDV genotypes in the western Brazilian Amazon region: a preliminary report. Am J Trop Med Hyg. 2006; 75: 475–9.
  230. Botelho-Souza LF, Souza Vieira D, de Oliveira Dos Santos A, Cunha Pereira AV,Villalobos-Salcedo JM. Characterization of the genotypic profile of Hepatitis Delta virus: isolation of HDV Genotype-1 in the western Amazon region of Brazil. Intervirology. 2015; 58: 166–71.
  231. Imazeki F, Omata M, Ohto M. Heterogeneity and evolution rates of delta virus RNA sequences. J Virol. 1990; 64: 5594–9.
  232. Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol. 2001; 82: 2709 – 18.
  233. Alvarado-Mora MV, Fernandez MFG, Gomes-Gouvêa MS, de Azevedo Neto RS, Carrilho FJ, Pinho JRR. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation? PLoS One. 2011;6:e18888.
  234. Gomes-Gouvêa MS, do Pereira Soares MC, Guedes de Carvalho Mello IMV, Brito EMF, de Pereira Moia LJM, Bensabath G, et al. Hepatitis D and B virus genotypes in chronically infected patients from the eastern Amazon Basin. Acta Trop. 2008; 106: 149–55.
  235. Gomes-Gouvêa MS, Soares MCP, Bensabath G, de Carvalho-Mello IMVG, Brito EMF, Souza OSC, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol. 2009; 90: 2638–43.
  236. Alvarado-Mora MV, Romano CM, Gomes-Gouvêa MS, Gutierrez MF, Carrilho FJ, Pinho JRR. Dynamics of hepatitis D (delta) virus genotype 3 in the Amazon region of South America. Infect Genet Evol. 2011; 11: 1462–8.
  237. Ma S-P, Sakugawa H, Makino Y, Tadano M, Kinjo F, Saito A. The complete genomic sequence of hepatitis delta virus genotype IIb prevalent in Okinawa, Japan. J Gen Virol. 2003; 84: 461–4.
  238. Barros LMF, Gomes-Gouvêa MS, Pinho JRR, Alvarado-Mora MV, Dos Santos A, Mendes-Corrêa MCJ, et al. Hepatitis Delta virus genotype 8 infection in Northeast Brazil: inheritance from African slaves? Virus Res. 2011; 160: 333–9.
  239. Buti M, Esteban R, Roggendorf M, Fernandez J, Jardi R, Rashofer R, et al. Hepatitis D virus RNA in acute delta infection: serological profile and correlation with other markers of hepatitis D virus infection. Hepatology. 1988; 8: 1125–9.
  240. Jardi R, Buti M, Rodriguez-Frias F, Garcia-Lafuente A, Sjogren MH, Esteban R, et al. Clinical significance of two forms of IgM antibody to hepatitis delta virus. Hepatology. 1991; 14: 25–8.
  241. Buti M, Lopez-Talavera JC, Allende H, Jardi R, Esteban R, Guardia J. Serological diagnosis of chronic delta infection: correlation between serological markers and hepatitis delta virus RNA in hepatic tissue. Prog Clin Biol Res. 1993; 382: 319–23.
  242. Jardi R, Buti M, Rodriguez F, Cotrina M, Allende H, Esteban R, et al. Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. J Virol Methods. 1994; 50: 59–66.
  243. Jardi R, Buti M, Cotrina M, Rodriguez F, Allende H, Esteban R, et al. Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delta infection. Hepatology. WB Saunders. 1995; 21: 25–9.
  244. Buti M, Jardi R, Allende H, Cotrina M, Rodriguez F, Viladomiu L, et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol. 1996; 49: 66–9.
  245. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. (London, England) NIH Public Access. 2008; 371: 838–51.
  246. Niro GA, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep. 2012; 14: 9–14.
  247. Verme G, Amoroso P, Lettieri G, Pierri P, David E, Sessa F, et al. A histological study of hepatitis delta virus liver disease. Hepatology. 1986;6:1303–7.
  248. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012; 32: 228–36.
  249. Smedile A., Ciancio A., Rizzetto M., Hepatitis D.Hepatitis D virus.in: Richman D.D. Whitley R. J. Hayden F.G. Clinical virology. ASM Press, Washington DC2002: 1227-1240.
  250. Casey J. L., Brown T. L., Colan E.J., Wignall F.S. , Gerin J.L., A genotype of hepatitis D virus that occurs in northern South America.Proc Natl Acad Sci USA. 1993; 90: 9016-9020.
  251. Niro G.A.,Smedile A.,Andriulli A., Rizzetto M., Gerin J. L., Casey J.L.,The predominance of hepatitis delta virus genotype I among chronically infected Italianpatients.Hepatology. 1997; 25: 728-734.
  252. Hsu S. C., Syu W. J., Ting L. T., Wu J.C.,Immunohistochemicaldifferentiation of hepatitis D virus genotypes. Hepatology. 2000; 32: 1111-1116.
  253. Smedile A., Rizzetto M., Gerin J. L., Advances in hepatitis D virus biology and disease.in: Boyer J. L. Okner R.K. Progress in liver disease. vol. 12. WBSaunders, Philadelphia1994: 157-175.
  254. Farci P., Gerin J. L., Aragona M., Lindsey I., Crivelli O., Balestrieri A., et al., Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus.mJ Am Med Assoc. 1986; 255: 1443-1446.
  255. Borghesio E.,Rosina F.,Smedile A., Lagget M., Niro M.G., Marinucci G., et al., Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology. 1998; 27: 873-876.
  256. Rizzetto M., Rosina F., Hepatitis D. Hepatitis D virus: treatment. in: Zuckerman A.J. Thomas H.C. Viral hepatitis. Churchill Livingstone, Edinburgh 1997: 387-393.
  257. Berk L., de Man R.A., Housset C., Berthelot P., Schalm S.W. ,Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Prog Clin Biol Res. 1991; 364: 411-420.
  258. Garripoli A., Di Marco V., Cozzolongo R., Costa C., Smedile A., Fabiano A., et al., Ribavirin treatment for chronic hepatitis D: a pilot study.Liver. 1994; 14: 154-157.
  259. Yurdaydin C., Bozkaya H.,Gurel S.,Tillmann H. L., Aslan N., Okcu-Heper A., et al., Famciclovir treatment of chronic delta hepatitis .J Hepatol. 2002; 37: 266-271.
  260. Lau D. T., Doo E., Park Y., Kleiner D.E., Schmid P., Kuhns M. C., et al., Lamivudine for chronic delta hepatitis.Hepatology. 1999; 30: 546-549.
  261. Wolters L. M., van Nunen A.B., Honkoop P., Vossen A. C., Niesters H. G., Zondervan P.E., et al., Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.J Viral Hepat. 2000; 7: 428-434.
  262. Rosina F., Pintus C., Meschievitz C., Rizzetto M., A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study.Hepatology. 1991; 13: 1052-1056.
  263. Farci P.,Mandas A.,Coiana A.,Lai M.E., Desmet V., Van Eyken P., et al., Treatment of chronic hepatitis D with interferon alfa-2a. N. Engl. J. Med. 1994; 330: 88-94.
  264. Lau J. Y., King R.,Tibbs C.J.,Catterall A.P.,Smith H.M.,Portmann B. C., et al., Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection.J Med Virol. 1993; 39: 292-296
  265. Battegay M., Simpson L.H.,Hoofnagle J.H.,Sallie R., Di Bisceglie A.M.,Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol. 1994 ; 44: 389-392.
  266. Marzano A., Ottobrelli A.,Spezia C.,Daziano E. , Soranzo M. L., Rizzetto M.,Treatment of early chronic delta hepatitis with lymphoblastoid alpha interferon : a pilot study. Ital J Gastroenterol. 1992 ; 24: 119-121.
  267. Hadziyannis S. J. Use of alpha-interferon in the treatment of chronic deltahepatitis.J.,Hepatol. 1991; 13: S21-S26.
  268. Gaudin J. L., Faure P., Godinot H., Gerard F., Trepo C., The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995; 15: 45-52.
  269. Farci P., Chessa L. , Peddis G. ,Strazzera R.,Pascariello E. , Orgiana G., et al.Influence of alpha interferon (IFN) on the natural history of chronic hepatitis D: dissociation of histologic andvirologicresponse.Hepatology. 2000; 32: 222 A.
  270. Lau D. T., Kleiner D. E., Park Y., Di Bisceglie A. M., Hoofnagle J. H., Resolution of chronic delta hepatitis after 12 years of interferon alfatherapy.Gastroenterology. 1999; 117 : 1229-1233.